Posted by Michael Wonder on 16 Jul 2016
Outcomes from the May 2016 PTAC meeting
15 July 2016 - The outcomes from the May 2016 PTAC meeting are now available.
The PTAC recommended the listing of three new medicines: nivolumab (Opdivo), selexipag (Uptravi) and sapropterin dihydrochloride (Kuvan).
PHARMAC is yet to publish funding applications it has received since the November 2015 PTAC meeting.
